Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose :Treatment options for patients with advanced gastric cancer remain limited. Few studies have investigated the efficacy and tolerability of the combination regimen of oxaliplatin and 5-fluorouracil with leucovorin for patients with advanced gastric cancer. The goal of this study was to examine the efficacy and toxicity of a modified FOLFOX-6 (mFOLFOX-6) regimen as a first-line chemotherapy regimen for patients with advanced gastric cancer. Materials and Methods :From March, 2006, to December, 2007, 82 patients with advanced gastric cancer received 100 mg/m2 oxaliplatin and 100 mg/m2 leucovorin on the first day of treatment, followed by 2,400 mg/m2 of 5-fluorouracil on the first and second days of treatment every 2 weeks as a first-line treatment. Results :The median age of the enrolled patients was 62 years (range; 30∼75). Out of 82 patients, 34 cases (41.5%) were recurrent cases after curative resection, and the other 48 cases were unresectable or non-curative resectable cases. Their response was evaluated every 6 weeks. The overall response rate was 40.2%, with 2 (2.4%) complete response and 31 (37.8%) partial responses. The median time to progression (TTP) and overall survival (OS) time were 6.0 months (95% confidence interval [CI]: 4.69∼7.31) and 13.0 months (7.99∼18.0), respectively. The grade 3∼4 hematologic toxicities observed included neutropenia (34.1%), thrombocytopenia (7.3%), and anemia (1.2%). The gastrointestinal toxicities observed included grade 3∼4 nausea (9.8%) and vomiting (7.3%). Six patients (7.3%) experienced grade 3 neuropathy. No treatment-related deaths were recorded. Conclusion :The modified FOLFOX-6 regimen is effective and well tolerated as a first-line chemotherapy regimen for patients with advanced gastric cancer.
Abstract
Purpose :Treatment options for patients with advanced gastric cancer remain limited. Few studies have investigated the efficacy and tolerability of the combination regimen of oxaliplatin and 5-fluorouracil with leucovorin for patients with advanced gastric cancer. The goal of this study was to examine the efficacy and toxicity of a modified FOLFOX-6 (mFOLFOX-6) regimen as a first-line chemotherapy regimen for patients with advanced gastric cancer. Materials and Methods :From March, 2006, to December, 2007, 82 patients with advanced gastric cancer received 100 mg/m2 oxaliplatin and 100 mg/m2 leucovorin on the first day of treatment, followed by 2,400 mg/m2 of 5-fluorouracil on the first and second days of treatment every 2 weeks as a first-line treatment. Results :The median age of the enrolled patients was 62 years (range; 30∼75). Out of 82 patients, 34 cases (41.5%) were recurrent cases after curative resection, and the other 48 cases were unresectable or non-curative resectable cases. Their response was evaluated every 6 weeks. The overall response rate was 40.2%, with 2 (2.4%) complete response and 31 (37.8%) partial responses. The median time to progression (TTP) and overall survival (OS) time were 6.0 months (95% confidence interval [CI]: 4.69∼7.31) and 13.0 months (7.99∼18.0), respectively. The grade 3∼4 hematologic toxicities observed included neutropenia (34.1%), thrombocytopenia (7.3%), and anemia (1.2%). The gastrointestinal toxicities observed included grade 3∼4 nausea (9.8%) and vomiting (7.3%). Six patients (7.3%) experienced grade 3 neuropathy. No treatment-related deaths were recorded. Conclusion :The modified FOLFOX-6 regimen is effective and well tolerated as a first-line chemotherapy regimen for patients with advanced gastric cancer.
참고문헌 (23)
- Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~168 (1997)
- Janunger KG, "A systematic overview of chemotherapy effects in gastric cancer", Acta Oncol, 40, pp.309~326 (2001)
- Kohne CH, "Developments in the treatment of gastric cancer in Europe", Oncology, 14, pp.22~25 (2000)
- Wils J, "Chemotherapy of metastatic gastric cancer", Gan To Kagaku Ryoho, 27, pp.395~398 (2000)
- Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 358, pp.36~46 (2008)
- Van Cutsem E, "Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group", J Clin Oncol, 24, pp.4991~4997 (2006)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- Goldberg RM, "A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer", J Clin Oncol, 2, pp.23~30 (2004)
- Becouarn Y, "Oxaliplatin: available data in noncolorectal gastrointestinal malignancies", Crit Rev Oncol Hematol, 40, pp.265~272 (2001)
- Cavanna L, "Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)", Am J Clin Oncol, 26, pp.371~375 (2006)
- Louvet C, "Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients", J Clin Oncol, 20, pp.4543~4548 (2002)
- Caussanel JP, "Phase I trial of 5- day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate", J Natl Cancer Inst, 82, pp.1046~1050 (1990)
- Al-Batran SE, "Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer", J Clin Oncol, 22, pp.658~663 (2004)
- Ohtsu A, "Chemotherapy for metastatic gastric cacner: past, present, and future", J Gastroenterol, 43, pp.256~264 (2008)
- Dank M, "Andormized phase 3 trials of irinotecan (CPT-11)+5FU", folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients, 2005, pp.23, 16~
- Boku N, "Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)", J Clin Oncol, 25(18) (2007)
- Narahara H, "Randomized phase III study of S-1 alone versus S-1+cisplatin in the treatment for advanced gastric cancer (the SPIRITS trials) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer", J Clin Oncol, 25(18) (2007)
- Hebbar M, "Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)", Cancer invest, 24, pp.154~159 (2006)
- Jee Hyun Kim, "Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer", Journal of Korean Medical Science, 20(5), pp.806~810 (2005), 대한의학회
- Hwang WS, "Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil", leucovorin as first-line chemotherapy in patients with advanced gastric cancer, 2008, pp.19, 283~288
- De Vita F, "A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients", Br J Cancer, 92, pp.1644~1649 (2005)
- Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie", J Clin Oncol, 26, pp.1435~1442 (2008)
- Maindrault-Goebel F, "Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5- fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)", Ann Oncol, 11, pp.1477~1483 (2000)